Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Trial of Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma

NCT04551430 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT04551430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04551430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Trial of Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 5, 2021
Completion date
February 1, 2029
Enrollment
105 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic soft-tissue sarcoma